Searchable abstracts of presentations at key conferences in endocrinology

ea0016p134 | Clinical cases | ECE2008

Optimization of chronic disease patient management: a pilot project on Sandostatin® LAR® treatment via homecare service

Roemmler J , Schopohl J , Seibling S , Petersenn S , Rinke A , Gress T M

In chronic diseases patient (pat) often need continuous med treatment. In acromegaly and neuroendocrine tumors (GEP-NET), long term monthly injections of somatostatin analogues as Sandostatin® LAR® (SA®) are the treatment of choice. Problems regarding pat management and drug application might arise in not-specialized centers such as general practicioners (GP). To optimize patÂ’ management and compliance a homecare project* wa...

ea0041ep605 | Endocrine tumours and neoplasia | ECE2016

Real life data on Lanreotide Autogel in the treatment of patients with neuroendocrine tumors (NET) – an interim analysis from SOPRANo study

Rinke Anja , Muller Lothar , Maintz Christoph , Bolling Claus , Raderer Markus , Christ-Crain Mirjam , Hoffmanns Philipp , Chevts Vitali , Houchard Aude , Petersenn Stephan

Introduction: This non-interventional study assesses real-life use and potential predictive parameters for lanreotide (LAN) in pts with either acromegaly (ACRO) or NET over a period of 24 months. We present a pre-specified interim analysis after first 6 months of therapy.Methods: The primary objective is to evaluate the long term treatment response under LAN and to correlate it with early changes of biochemical markers. The planned sample size is 152 (76...